MedMen Releases Preliminary Second Quarter 2019 Systemwide Revenue Results

LOS ANGELES--()--MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF) (FSE: A2JM6N) announced today unaudited systemwide revenue for its fiscal 2019 second quarter ended December 29, 2018. Across the Company’s operations in California, Nevada, New York and Arizona, systemwide revenue was US$29.9 million (CA$39.7 million). This represents a 40% quarter-over-quarter increase over its fiscal 2019 first quarter ended September 30, 2018. Systemwide revenue, pro forma for pending acquisitions that have not yet closed, was US$49.5 million (CA$65.7 million) for the quarter. For the second quarter, gross margin across its retail operations was 54%1, compared to 45% in the previous quarter. The Company is expected to post its fiscal 2019 second quarter results in February.

                        Expected
Q1 2019 Q2 2019 % Closing
(Currency in USD)       Actual       Actual       Change       (Fiscal)
Systemwide Revenue $ 21.4 $ 29.9 40 % --

Revenue from Pending Acquisitions2

$ 17.9 $ 19.6 10 %
PharmaCann (National) Q4 2019
Level Up (Arizona) Q3 2019
Buddy’s (California) Q3 2019
Seven Point (Illinois) Q3 2019
Ann Arbor (Michigan)3                               Q1 2020
Total Pro Forma Revenue       $ 39.3       $ 49.5       26 %        
 
End of Quarter:              
Retail Licenses      

77

 

 
Operational Stores (Including Pending Acquisitions)      

31

 

   
 

Systemwide retail revenue for the quarter, including revenue from pending announced acquisitions, is based on 31 retail stores that were operational at the end of the quarter. This includes the MedMen Paradise location near McCarran International Airport in Las Vegas, which opened in October, and the MedMen Scottsdale location in Arizona, which opened in December through the closing of the Monarch acquisition. The operational retail locations, including pending acquisitions, represent 40% of the 77 total stores that the Company is licensed for across 12 states.

Strong systemwide retail revenue for the quarter is primarily attributable to MedMen’s stores in Southern California’s recreational market. In California, the Company’s eight retail locations reported a combined US$23.7 million (CA$31.4 million) in revenue, which represents a 27% quarter-over-quarter increase. Cowen’s most recent estimate projects California will be a US$11 billion market by the end of 20304.

“California is the prize of the cannabis industry and the performance of our stores, quarter-over-quarter, is a reflection of our continued execution in our home state,” said Adam Bierman, MedMen chief executive officer and co-founder.

In addition to growing revenue at its existing locations, the Company has 16 new locations slated to open during calendar year 2019, including 12 locations in Florida, where the Company is licensed for up to 30 locations. The Company is set to open four retail stores in Florida in the next 90 days, which include locations in Miami Beach, Orlando, West Palm Beach and Key West.

ABOUT MEDMEN:

MedMen Enterprises is a leading cannabis company in the U.S. with assets and operations across the country. Based in Los Angeles, MedMen brings expertise and capital to the cannabis industry and is one of the nation’s largest financial supporters of progressive marijuana laws. Visit http://www.medmen.com

USD/CAD of $0.7543 as of January 16, 2019.

1 Total cost of goods sold across the Company’s retail operations was $16.2 million during the quarter

2 Includes unaudited net revenue from retail stores and licenses to be acquired through pending acquisitions

3 During the quarter, the Company signed a definitive agreement to acquire a retail operation in Michigan through a combination of cash and shares. The Company does not disclose deal values for transactions it deems immaterial from a purchase price standpoint.

4 Cowen Group per “Cannabis: $75B Opportunity; Category Cross-Currents Keep Us Cautious on Booze”

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMen’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMen’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, expectations regarding the Arizona cannabis market and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, MedMen is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedMen to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, MedMen has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws and compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although MedMen believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and MedMen does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to MedMen or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE: MedMen Enterprises

Contacts

MEDIA CONTACT:
Briana Chester
Senior Publicist
Email: briana.chester@medmen.com
(424) 888-4260

INVESTOR RELATIONS CONTACT:
Stéphanie Van Hassel
Head of Investor Relations
Email: investors@medmen.com
(323) 705-3025

Release Summary

MedMen Releases Preliminary Second Quarter 2019 Systemwide Revenue Results

Contacts

MEDIA CONTACT:
Briana Chester
Senior Publicist
Email: briana.chester@medmen.com
(424) 888-4260

INVESTOR RELATIONS CONTACT:
Stéphanie Van Hassel
Head of Investor Relations
Email: investors@medmen.com
(323) 705-3025